Navigation Links
VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
Date:8/19/2008

- First Product Developed from the VisEn-Merck & Co., Inc. Biomarker Imaging Program -

- Expands VisEn's Leading Fluorescence Molecular Imaging Agent Portfolio and Broadens Applications in Key Areas of Disease Research and Drug Development -

BEDFORD, Mass., Aug. 19 /PRNewswire/ -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its IntegriSenseTM fluorescence in vivo imaging agent product line. The agent is the first product developed out of the Merck-VisEn Biomarker Imaging research collaboration announced in 2007, and will enable researchers to image and assess the role of integrin alpha v beta 3 in disease progression and therapeutic response in vivo.

IntegriSense is an optimized in vivo fluorescence imaging agent targeting integrin alpha v beta 3, a key biomarker closely associated with disease-related vascularity and angiogenesis. The agent was developed to enable in vivo imaging of integrin alpha v beta 3 expression in order to measure and monitor aspects of disease progression and therapeutic response in disease states including oncology, cardiovascular disease, and bone disease.

"The integrin alpha v beta 3 protein plays an important key role in many disease pathways, which is one of the key reasons we selected this as a first imaging target with our collaborators at Merck," said Kirtland Poss, President and CEO of VisEn Medical. "IntegriSense should enable researchers to drive valuable new insights into disease progression and therapeutic mechanisms of action in vivo. We are pleased to be providing our customers the continually expanding ability to generate such rich information on their disease biologies and pathways of interest."

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic Imaging Systems (FMT), provide the industry's most robust fluores
'/>"/>

SOURCE VisEn Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
2. VisEn Medical Raises $7 Million in Series B Financing
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's ... narrows down the product choices to a manageable shortlist of bench and floor ... to models that fit best with the customer’s industry and application. , ...
(Date:8/26/2015)... , Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... pre-clinical activities with respect to our Oral Amp ... a contract manufacturer," said Andrew Rae , ...
(Date:8/26/2015)...  Platform therapeutic company Symic Biomedical, Inc. ("Symic") ... Phase II SBIR grant from the National Institutes ... agent to reduce arteriovenous fistula (AVF) failures, a ... disease (ESRD) patients undergoing hemodialysis. The two-year project, ... Digestive and Kidney Diseases (NIDDK), will allow Symic ...
(Date:8/26/2015)... 2015 After litigating and negotiating patent ... to P2i United States patent RE43,651 ... the United States without any admission ... either party. As a result of the parties, settlement, the ... California dismissed the case without prejudice. ...
Breaking Biology Technology:METTLER TOLEDO Updates Online Scale Selection Tool 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3P2i Settles United States Litigation 2
... security to residences and private offices with their state-of-the-art fingerprint recognition ... schools and the military is now accessible to the public. ... ... biometric technology used to enhance Hollywood films like Mission Impossible is ...
... (Nasdaq: NLTX ), today announced that Peter Strumph, ... in the Biotech Industry,conference on Thursday, September 4, at ... York City. Mr. Strumph will provide a company,overview and ... The presentation will be webcast live and can ...
... a leader in health,care quality management solutions for ... approved the company as a vendor for the ... will automate the collection and submission of clinical,information ... to,hand-write data collection worksheets or manually enter data ...
Cached Biology Technology:BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices 2Nile Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference 2MDdatacor Designated as Approved Vendor by CMS for Physician Quality Reporting Initiative 2
(Date:8/4/2015)... ALBANY, N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) ... June 30, 2015. Highlights: , Second quarter ... increase from 2014 , Adjusted contract margins of ... EPS of $0.22, including a $0.05 decrease in EPS from royalties ... of $16 million "We are very pleased to ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... release is available in German . , In ... immune system must be able to recognize myriad different foreign ... Institute of Immunobiology and the Centre for Biological Signalling Studies ... immune system,s B-cells can be activated by numerous substances from ...
... know about smoking, diet, exercise and available methods ... approximately half of all cancers nationwide. ... will host its Ninth Annual International Conference on ... Convention Center, located in Philadelphia. Thousands of scientists ...
... new study from North Carolina State University finds that fish ... than fish that live much further away. The surprising finding ... selenium, found near such facilities, which unfortunately poses problems of ... at least 30 kilometers (km) from a coal-fired power plant ...
Cached Biology News:One lock, many keys 2Study: Fish near coal-fired power plants have lower levels of mercury 2
...
... a hydrolytic enzyme that catalyzes the ... glucose, maltose, maltotriose and,dextrins. The level ... the human,body are of clinical importance,1-3 ... enzymes for industry.4, The EnzChek Amylase ...
... The Jouan MSC series of ... comfortable working conditions and certification to ... automatic regulation ensures that the cabinets ... working conditions. Natural lighting, low noise ...
Rabbit polyclonal to STUB1 ( Abpromise for all tested applications). entrezGeneID: 10273 SwissProtID: Q9UNE7...
Biology Products: